**ADVANTAGE MULTI® (imidacloprid + moxidectin) Topical Solution**

**One-month topical control in clinical studies included the following: Macroparasites (mainly microfilariae), ticks, and adult fleas. However, for all clinical studies, flea infestations were controlled based on post-treatment flea experience reports. Not all adverse reactions are reported to Bayer. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship between the adverse event and the product.**

**SAFETY STUDIES: Topical Application in Dogs**

**Effective at 14 days**

**Treatments were well-tolerated**

**ADVERSE REACTIONS: Dogs Treated with Advantage Multi®**

**Dosage and Administration**: For the first 30 minutes after application, owners should keep dogs indoors or in a vehicle and separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion.

**off-label use**: Bayer HealthCare LLC ** Bayer, the Bayer Cross and the Bayer logo are trademarks of Bayer HealthCare LLC or its related companies.**